Valeria Manicardi

Dr. Valeria Manicardi


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MVMassimo Vicentini
Massimo Vicentini
PBPaola Ballotari
Paola Ballotari
FVFrancesco Venturelli
Francesco Venturelli
MOMarta Ottone
Marta Ottone
VMValeria Manicardi
Valeria Manicardi
PRPaolo Giorgi Rossi
Paolo Giorgi Rossi
Objective: To assess the effect of insulin on cancer incidence in type 1 (T1DM) and type 2 diabetes (T2DM). Methods: The cohort included all 401,172 resident population aged 20–84 in December 2009 and still alive on December 2011, classified for DM status. Drug exposure was assessed for 2009–2011 and follow up was conducted from 2012 to 2016 through the cancer registry. Incidence rate ratios (IRRs) were computed for all sites and for the most frequent cancer sites. Results: among residents, 21,190 people had diabetes, 2282 of whom were taking insulin; 1689 cancers occurred, 180 among insulin users. The risk for all site was slightly higher in people with T2DM compared to people without DM (IRR 1.21, 95% CI 1.14–1.27), with no excess for T1DM (IRR 0.73, 95% CI 0.45–1.19). The excess in T2DM remained when comparing with diet-only treatment. In T2DM, excess incidence was observed for liver and pancreas and for NETs: 1.76 (95% CI 1.44–2.17) and 1.37 (95% CI 0.99–1.73), respectively. For bladder, there was an excess both in T1DM (IRR 3.00, 95% CI 1.12, 8.02) and in T2DM (IRR1.27, 95% CI 1.07–1.50). Conclusions: Insulin was associated with a 20% increase in cancer incidence. The risk was higher for liver, pancreatic, bladder and neuroendocrine tumours.

24 September 2022 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
Giuseppina Tiziana RussoGiuseppina Tiziana Russo
Giuseppina Tiziana Russo
AGAnnalisa Giandalia
Annalisa Giandalia
ACAntonio Ceriello
Antonio Ceriello
PBP. Di Bartolo
P. Di Bartolo
GCG. Di Cianni
G. Di Cianni
SCS. De Cosmo
S. De Cosmo

5 March 2024 in Journal of Endocrinological Investigation
Verified
Journal Article
Open access
PDF file
AGAnnalisa Giandalia
Annalisa Giandalia
ANA. Nicolucci
A. Nicolucci
MMM. Modugno
M. Modugno
GLG. Lucisano
G. Lucisano
MRM. C. Rossi
M. C. Rossi
GRG. T. Russo
G. T. Russo
Aims: Opportunities and needs for starting insulin therapy in Type 2 diabetes (T2D) have changed overtime. We evaluated clinical characteristics of T2D subjects undergoing the first insulin prescription during a 15-year-observation period in the large cohort of the AMD Annals Initiative in Italy. Methods: Data on clinical and laboratory variables, complications and concomitant therapies and the effects on glucose control after 12 months were evaluated in T2D patients starting basal insulin as add-on to oral/non-insulin injectable agents, and in those starting fast-acting in add-on to basal insulin therapy in three 5-year periods (2005–2019). Results: We evaluated data from 171.688 T2D subjects who intensified therapy with basal insulin and 137.225 T2D patients who started fast-acting insulin. Overall, intensification with insulin occurred progressively earlier over time in subjects with shorter disease duration. Moreover, the percentage of subjects with HbA1c levels > 8% at the time of basal insulin initiation progressively decreased. The same trend was observed for fast-acting formulations. Clinical characteristics of subjects starting insulin did not change in the three study-periods, although all major risk factors improved overtime. After 12 months from the starting of basal or fast-acting insulin therapy, mean HbA1c levels decreased in all the three investigated time-periods, although mean HbA1c levels remained above the recommended target. Conclusions: In this large cohort of T2D subjects, a progressively earlier start of insulin treatment was observed during a long observation period, suggesting a more proactive prescriptive approach. However, after 12 months from insulin prescription, in many patients, HbA1c levels were still out-of-target.